Differential pricing structures are necessary for products with surrogate endpoints and to account for revolutionizing treatments in order to have a more sustainable value equation, according to Scott Ramsey, MD, PhD, of Fred Hutchinson Cancer Research Center.
Differential pricing structures are necessary for products with surrogate endpoints and to account for revolutionizing treatments in order to have a more sustainable value equation, according to Scott Ramsey, MD, PhD, of Fred Hutchinson Cancer Research Center.
Transcript (slightly modified)
The current trend in oncology in accelerated approvals in early phase results that use surrogate endpoints instead of overall survival. Do you see this as a sustainable model in the face of rising drug prices?
That model of using surrogate endpoints has been around for many years. What we’re seeing, instead of more use of surrogate endpoints, is more products coming out with surrogate endpoints. It is quite problematic in terms of the health spend trend, in oncology specifically, and it may need to be resolved by addressing limited evidence with differential pricing. In other words, when we have only intermediate endpoints we may have to have a different pricing structure than when we have overall survival as an endpoint.
Recent immuno-oncology agents have revolutionized cancer care. How can our health system sustain the cost of using these agents?
There are going to have to be different pricing structures. I would argue a little bit that they haven’t quite revolutionized cancer care. I think that they are an important step and in some diseases they have had substantial benefits but in others the benefits are much more modest and I think we need to account for that differential benefit with differential pricing, again bringing it back to a more sustainable value equation.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More